Myelodysplasia Treatment at the University of Colorado Cancer Center
At the University of Colorado Cancer Center, we see all kinds of blood cancers, from the rarest to the most common.
Because we specialize in myelodysplasia, we’ve cared for patients from all over the nation. And because we’re one of the leading research centers in the nation, you can count on taking advantage of the latest and greatest in cancer advancements.
Our expert team of highly-skilled doctors and support professionals tailor treatment, care and support to each unique individual. And this same team will be with you throughout your journey, from initial testing and support to treatment and aftercare.
Our dedication to a cure for cancer is unwavering. That’s why our 5-year survival rates are up to 30% higher than state, regional and national averages.
To begin your journey with a committed and caring team of myelodysplasia experts, call us today at (720) 848-0300.
What is Myelodysplasia?
Myelodysplastic syndromes (MDS) are a group of cancers that start in an early blood-forming cell in the bone marrow.
The marrow then produces too few red blood cells, white blood cells and often platelets. The disease can range from chronic and slow-growing to very severe, including acute myelogenous leukemia.
Myelodysplasia at a Glance
- From 2003 to 2007, an average of 11,954 new cases of myelodysplastic syndromes (MDS) were diagnosed each year.
- Overall, there are 4.3 cases of MDS per 100,000 people.
- Most cases occur after age 50, and it is more common in men than women.
- A possible cause of MDS (and some types of leukemia) is repeated exposure to benzene. Tobacco smoke is now the most common known cause of benzene exposure.